Valneva SE
World Trade Center Lyon, Tour Oxygène
10-12 boulevard Marius Vivier Merle
Lyon
69003
France
Tel: 33-4-78-76-61-01
Website: http://www.valneva.com/
About Valneva SE
Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.LEADERSHIP:
CEO: Thomas Lingelbach
CFO: Reinhard Kandera
144 articles about Valneva SE
-
Specialty vaccine company Valneva and Pfizer have reported positive Phase II data from their clinical trial evaluating a Lyme Disease vaccine candidate.
-
Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 Guidance
2/3/2022
Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2021 and provided full year 2022 revenue guidance.
-
Valneva Announces Initiation of Adolescent Phase 3 Trial for its Single-Shot Chikungunya Vaccine Candidate
1/31/2022
Valneva SE today announced the initiation of a Phase 3 trial in adolescents for its single-shot chikungunya vaccine candidate, VLA1553.
-
Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant
1/19/2022
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva’s inactivated COVID-19 vaccine candidate, VLA2001, neutralize the Omicron variant.
-
Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001
1/6/2022
Valneva SE, a specialty vaccine company, confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
-
Valneva and Scottish Enterprise in Advanced Discussions for Major Grant to Complete Livingston Site
12/23/2021
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is in advanced discussions, with Scottish Enterprise, for a multi-million pound grant which will enable it to fully complete its strategic manufacturing site in Livingston, Scotland.
-
Valneva Announces Positive Homologous Booster Data for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
12/16/2021
Valneva SE, a specialty vaccine company, announced positive homologous booster data from the Phase 1/2 study, of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
-
Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001
12/8/2021
ValnevaSE, a specialty vaccine company, announced the signing of an advance purchase agreement with the Kingdom of Bahrain for the supply of one million doses of the Company’s inactivated COVID-19 vaccine candidate VLA2001.
-
Valneva Comments on COV-Boost Clinical Trial Data
12/3/2021
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), today responded to data published from the COV-Boost COVID-19 vaccine trial, which investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines at different dose levels when administered as a third dose, or booster, to people primed with either Pfizer’s Comirnaty or AstraZeneca’s Vaxzevria.
-
Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001
12/2/2021
ValnevaSE, a specialty vaccine company, confirmed that the European Medicines Agency has started a rolling review of VLA2001, its whole-virus inactivated, adjuvanted COVID-19 vaccine candidate.
-
Valneva Reports Nine-Month 2021 Revenue and Cash
11/18/2021
Saint Herblain, November 18, 2021 – Valneva SE a specialty vaccine company, reported its revenue and cash balance for the first nine months of the year 2021.
-
Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001
11/10/2021
ValnevaSE, a specialty vaccine company, announced that the European Commission has approved an agreement pursuant to which Valneva would supply up to 60 million doses of VLA2001, its inactivated COVID-19 vaccine candidate, over two years including approximately 27 million doses in 2022.
-
Valneva Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to Approximately $102.0 Million
11/1/2021
Valneva SE announced that the underwriters of its global offering of an aggregate of 4,500,000 new ordinary shares, consisting of a private placement of 4,466,880 ordinary shares in Europe and other countries outside of the United States and a concurrent public offering of 16,560 American Depositary Shares, each representing two ordinary shares, have exercised in full their option to purchase up to 675,000 additional new ordinary shares in the form of 337,500 ADSs.
-
Valneva Announces the Pricing of its Global Offering of American Depositary Shares and Ordinary Shares
10/29/2021
Valneva SE announced the pricing of 4,500,000 ordinary shares in a global offering to specified categories of investors comprised of a public offering of 16,560 American Depositary Shares, each representing two ordinary shares, in the United States, and a concurrent private placement of 4,466,880 ordinary shares in certain jurisdictions outside of the United States.
-
Valneva Publishes Amendment to 2020 Universal Registration Document
10/26/2021
Valneva SE, a specialty vaccine company, announced the publication of an amendment filed with the French Financial Markets Authority on October 26, 2021 under the filing number D.21-0286-A01 to its 2020 Universal Registration Document, filed with the AMF on April 9, 2021 under the filing number D.21-0286.
-
Valneva Announces Launch of Proposed Global Offering of American Depository Shares and Ordinary Shares
10/26/2021
Valneva SE announced its intention to issue and sell, subject to market conditions, 5,500,000 of its ordinary shares in a global offering to specified categories of investors comprised of a public offering of its American Depositary Shares, each representing two ordinary shares, in the United States and a concurrent private placement of its ordinary shares in certain jurisdictions outside of the United States.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
-
COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial
10/18/2021
Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing vaccines, announced that Valneva SE reported positive topline results from the Phase 3 pivotal trial of VLA2001, their inactivated COVID-19 vaccine candidate using Dynavax's CpG 1018® adjuvant.
-
It proved itself superior to AZD1222 (ChAdOx1-S), the vaccine by Astrazeneca-Oxford, in terms of geometric mean titer for neutralization antibodies.